Table 2 Cox proportional hazards ratio model of primary outcomes
From: New risk score for predicting progression of membranous nephropathy
Univariate analysis HR (95% CI) | P | Multivariate analysis HR (95% CI) | P | HR (95% CI) from Bootstrap analysis | P | |
|---|---|---|---|---|---|---|
Age (years) | 1.09 (1.05–1.12) | < 0.01 | 1.04 (1.003–1.08) | 0.04 | 1.04 (1.01–1.08) | 0.01 |
Female | 0.62 (0.31–1.21) | 0.16 | – | – | – | – |
Albumin (g/l) | 0.90 (0.85–0.95) | < 0.01 | – | – | – | – |
Proteinuria (g/24 h) | 1.14 (1.06–1.21) | < 0.01 | 1.09 (1.01–1.18) | 0.03 | 1.09 (1.02–1.16) | < 0.01 |
eGFR (ml/min/1.73 m2) | 0.96 (0.95–0.97) | < 0.01 | 0.97 (0.96–0.99) | < 0.01 | 0.97 (0.96–0.99) | < 0.01 |
Microscopic hematuria | 0.78 (0.40–1.50) | 0.45 | – | – | – | – |
Triglyceride (mmol/l) | 1.16 (0.97–1.39) | 0.11 | ||||
Cholesterol (mmol/l) | 1.06 (0.93 ~ 1.22) | 0.39 | – | – | – | – |
Uric acid (μmol/l) | 1.00 (0.99–1.01) | 0.20 | – | – | – | – |
Serum PLA2R antibody (RU/l) | 1.00 (0.99–1.00) | 0.28 | – | – | – | – |
Pathological characteristics | – | – | – | – | ||
Stages I and II | 1.00 (0.46–2.22) | 0.99 | – | – | – | – |
≥ 50% interstitial fibrosis | 6.12 (2.54–14.73) | < 0.01 | – | – | – | – |
PLA2R staining positive | 26.08 (0.00–3 × 106) | 0.59 | – | – | – | – |
IgG1 positive | 0.99 (0.11–9.50) | 0.99 | – | – | ||
IgG4 positive | 0.40 (0.04–3.63) | 0.40 | – | – |